Dicot Pharma Dicot Pharma
På svenska

Phase 2a study Shows Positive Results

The proof of concept study demonstrated that the drug candidate LIB-01 improves erectile function — with sustained effect at week eight.

Dicot Pharma develops a new generation potency drugs

Over 500 million men worldwide suffer from erectile dysfunction and premature ejaculation. Dicot Pharma is developing an entirely new potency drug aimed at creating a treatment with longer duration, fewer side effects, and effectiveness for a significantly broader group compared to existing market alternatives. Clinical studies are currently underway, with Phase 2a completed.

Press Releases

Dicot Pharma’s World in Numbers

Approx.
billion SEK/year
The global sales of erectile dysfunction treatments.
Approx.
percent
The proportion of men with erectile dysfunction who discontinue treatment with current medications.
At least
days
LIB-01's duration according to phase 2a-study.
percent
The number of shareholders has doubled in one year.

Q3 Report Now Available

Read the newly published quarterly report. Or see CEO Elin Trampe, CSO Charlotta Gauffin, and CFO Björn Petersson in an interview on October 24 with Direkt Studios. Here, they comment on the quarter and answer questions regarding the new Phase 2a results.

Financial calendar and events

Dicot Pharma highlighted in Oppenheimer’s report

The global investment bank Oppenheimer has published an equity research report where Dicot Pharma and LIB-01 for the treatment of erectile dysfunction are singled out as being of particular interest. The report is part of Oppenheimer’s focus on longevity as the next major trend for biotech investors and highlights a clear link between erectile dysfunction and healthy aging.